Dirk Finsinger

You can dig deep into scientific questions, but you always have a specific objective in mind.

Perspective

Working as a scientist in an industrial environment is facinating for me. You can dig deep into scientifc questions, but you always have a specific objective in mind:  how can I translate this scientific idea into a useful strategy to benefit human health and finally contribute to identify new medicines.This on the one hand restricts the breadth of research you can do, but forces you to really focus on the decisive questions and experiments. Having this in mind is a fantastic driver to move things forward in a meaningfull way. Our company has created a great interdisciplinary setup that allows scientist to interact and exchange intensively beween the different disciplines and allows a scientist to not only focus on his expert discipline but see the "whole picture".

You can dig deep into scientific questions, but you always have a specific objective in mind

Dirk Finsinger

Director Medicinal Chemistry, Innovation & Externalization, Discovery and Development Tech

Profile

Joined Merck KGaA, Darmstadt, Germany: 2001

Key research fields and topics:

  • Medicinal Chemistry
  • Compound Screening
  • Early research project pipeline
  • Novel Technologies
  • Outsourcing

CV & Scientific activities

CV: Education

CV: Education

1997
PhD, Technical University Munich (TUM)
1988 - 1990
Two year postdoc at the Institute of Experimental Oncology and Therapy Research of the University Hospital, TUM. Main focus was to create transport vehicles for plasmid DNA to enable applications in non-viral gene transfer. Organic synthesis and cell-biology, assay-technology.

CV: Professional Career

CV: Professional Career

2001
Lab Head and Project Leader, Medicinal Chemistry and Oncology, Merck KGaA, Darmstadt, Germany
2008
Head Medicinal Chemistry Lead Finding, Merck KGaA, Darmstadt, Germany
2010
Group Leader Medicinal Chemistry, Merck KGaA, Darmstadt, Germany
2016 - 2017
Director Early NCE Pipeline & Advancing Technologies, Merck KGaA, Darmstadt, Germany
2017 - 2019
Director Medicinal Chemistry, Innovation & Externalization, Merck KGaA, Darmstadt, Germany
since 2019
Director Medicinal Chemistry, Early Pipeline Technologies, Merck KGaA, Darmstadt, Germany

References

Patents

  1. Preparation of tetrahydrotetrazolo[1,5-a]pyrazines as ROR-gamma inhibitors By Finsinger, Dirk; Wucherer-Plietker, Margarita; Blume, Beatrix WO 2015090507 A1 20150625,
  2. Preparation of tetrahydrobenzoisoxazole and tetrahydroindazole derivatives as modulators of the mitotic motor protein By Schiemann, Kai; Finsinger, Dirk; Zenke, Frank US 20100022530 A1 20100128
  3. Preparation of pyrrolopyridinylpyrimidin-2-ylamines as PDK1 kinase inhibitors By Wuchrer, Margarita; Bruge, David; Finsinger, Dirk; Graedler, Ulrich; Dorsch, Dieter; Esdar, Christina WO 2010000364 A1 20100107, Language: German, Database: CAPLUS
  4. Preparation of pyrrolopyridinylpyrimidin-2-ylamines as PDK1 kinase inhibitorsBy Wuchrer, Magarita; Bruge, David; Finsinger, Dirk; Graedler, Ulrich; Dorsch, Dieter; Esdar, Christina DE 102008031517 A1 20100107
  5. Preparation of tetrahydroquinolines as antitumor agentsBy Schiemann, Kai; Finsinger, Dirk; Amendt, Christiane; Zenke, Frank DE 102007013855 A1 20080925
  6. Preparation of tetrahydroquinolines as antitumor agentsBy Schiemann, Kai; Finsinger, Dirk; Amendt, Christiane; Zenke, Frank DE 102007013854 A1 20080925
  7. Preparation of tetrahydroquinolines as antitumor agentsBy Schiemann, Kai; Finsinger, Dirk; Amendt, Christiane; Zenke, Frank WO 2008113456 A1 20080925
  8. Preparation of tetrahydroquinolines as antitumor agentsBy Schiemann, Kai; Finsinger, Dirk; Amendt, Christiane; Zenke, Frank WO 2008113451 A1 20080925
  9. Preparation of tetrahydrobenzoisoxazoles and tetrahydroindazoles as modulators of the mitotic motor protein By Schiemann, Kai; Finsinger, Dirk; Zenke, Frank WO 2008080455 A1 20080710
  10. Preparation of diazepinones as PDK1 kinase inhibitors By Schulz, Melanie; Burgdorf, Lars Thore; Finsinger, Dirk; Blaukat, Andree; Greiner, Hartmut; Esdar, Christina; Kreysch, Hans-Georg; Henzler, Tanja DE 102005061655 A1 20070628
  11. Preparation of tetrahydroquinoline derivatives for use in the treatment of tumorsBy Staehle, Wolfgang; Bruge, David; Schiemann, Kai; Finsinger, Dirk; Buchstaller, Hans-Peter; Zenke, Frank; Amendt, Christiane DE 102005027169 A1 20061214
  12. Preparation of tetrahydroquinolines for use in the treatment of tumors By Schiemann, Kai; Bruge, David; Buchstaller, Hans-Peter; Emde, Ulrich; Finsinger, Dirk; Amendt, Christiane; Zenke, Frank DE 102005027168 A1 20061214
  13. Preparation of quinazolinones as mitosis cell division modulatorsBy Buchstaller, Hans-Peter; Finsinger, Dirk; Schiemann, Kai; Emde, Ulrich; Zenke, Frank; Amendt, ChristianeWO 2006125555 A2 20061130
  14. Preparation of 2-benzyl-1(2H)-phthalazinones as antitumor agentsBy Buchstaller, Hans-Peter; Finsinger, Dirk; Schiemann, Kai; Emde, Ulrich; Zenke, Frank; Amendt, ChristianeWO 2006097176 A1 20060921
  15. Preparation of tetrahydro- and dihydroquinazolinones as protein kinase (especially VEGFR kinase) modulators By Finsinger, Dirk; De Meijere, ArminWO 2006094604 A1 20060914
  16. Preparation of 1-methylene-2-phenylindenes as mitosis cell division modulators By Finsinger, Dirk; Bruge, David; Buchstaller, Hans-Peter; Emde, Ulrich; Schiemann, Kai; Staehle, Wolfgang; Amendt, Christiane; Heiss, Nina; Zenke, FrankDE 102005010000 A1 20060907
  17. Preparation of fused tetrahydroquinolines as anticancer drugs. By Schiemann, Kai; Bruge, David; Buchstaller, Hans-Peter; Finsinger, Dirk; Staehle, Wolfgang; Amendt, Christiane; Emde, Ulrich; Zenke, FrankWO 2006002726 A1 20060112
  18. Preparation of dihydrobenzothiophenes as antitumor agents By Finsinger, Dirk; Anzali, Soheila; Frech, Matthias; Gleitz, Johannes; Heiss, Nina; Hock, Bjoern; Schiemann, Kai; Zenke, FrankWO 2005108355 A2 20051117
  19. Preparation of isoquinoline derivatives as kinase inhibitors By Buchstaller, Hans-Peter; Burgdorf, Lars; Finsinger, Dirk; Amendt, Christiane; Grell, Matthias; Sirrenberg, Christian; Zenke, FrankWO 2005082858 A2 20050909
  20. Preparation of aryl semicarbazide derivatives as kinase inhibitors By Buchstaller, Hans-Peter; Finsinger, Dirk; Stieber, Frank; Wiesner, Matthias; Amendt, Christiane; Sirrenberg, Christian; Zenke, Frank; Grell, Matthias WO 2005082853 A1 20050909
  21. Preparation of heteroaryl substituted tetrahydroquinolines as inhibitors of Eg5 proteinsBy Schiemann, Kai; Anzali, Soheila; Drosdat, Helga; Emde, Ulrich; Finsinger, Dirk; Gleitz, Johannes; Hock, Bjoern; Reubold, Helmut; Zenke, FrankWO 2005063735 A1 20050714
  22. Preparation and formulations of diacylhydrazine derivatives capable of inhibiting raf-kinases By Finsinger, Dirk; Buchstaller, Hans-Peter; Burgdorf, Lars; Amendt, Christiane; Grell, Matthias; Sirrenberg, Christian; Zenke, FrankWO 2005058832 A1 20050630
  23. Preparation of arylpyrrolecarboxamides as Raf kinase inhibitors for treatment of tumors. By Finsinger, Dirk; Buchstaller, Hans-Peter; Burgdorf, Lars; Wiesner, Matthias; Amendt, Christiane; Grell, Matthias; Sirrenberg, Christian; Zenke, FrankDE 10354060 A1 20050602
  24. Preparation of malonamide derivatives useful as raf-kinase inhibitorsBy Bruge, David; Buchstaller, Hans-Peter; Wiesner, Matthias; Finsinger, Dirk; Baumgarth, Manfred; Sirrenberg, Christian; Zenke, Frank; Amendt, Christiane; Grell, MatthiasWO 2005005389 A2 20050120
  25. Preparation of benzimidazole amides as raf kinase inhibitors By Buchstaller, Hans-Peter; Finsinger, Dirk; Wiesner, Matthias; Burgdorf, Lars; Amendt, Christiane; Grell, Matthias; Sirrenberg, Christian; Zenke, Frank WO 2005004864 A1 20050120
  26. Preparation of arylpyrazoles as serotonin 5-HT2A and 5-HT2C receptor antagonists By Schiemann, Kai; Ackermann, Karl-August; Arlt, Michael; Finsinger, Dirk; Schadt, Oliver; Van Amsterdam, Christoph; Bartoszyk, Gerd; Seyfried, Christoph DE 10315572 A1 20041014
  27. Preparation of arylpyrazoles as serotonin 5-HT2A and/or 5-HT2C receptor antagonists. By Schadt, Oliver; Arlt, Michael; Finsinger, Dirk; Schiemann, Kai; Van Amsterdam, Christoph; Bartoszyk, Gerd; Seyfried, Christoph DE 10315569 A1 20041014
  28. Preparation of pyridinyloxybenzylureas as RAF kinase inhibitors.By Buchstaller, Hans-Peter; Wiesner, Matthias; Schadt, Oliver; Amendt, Christiane; Zenke, Frank; Sirrenberg, Christian; Grell, Matthias; Finsinger, Dirk WO 2004037789 A2 20040506
  29. Copolymers of amphiphilic polymers and peptides for coating of DNA-polycation complexes for transfection and gene therapyBy Plank, Christian; Finsinger, Dirk EP 1063254 A1 20001227
  30. Synthesis and therapeutic uses of cyclo-peptide derivatives as integrin inhibitorsBy Meyer, Joerg; Nies, Berthold; Finsinger, Dirk; Jonczyk, Alfred; Kessler, Horst; Kantlehner, Martin DE 19755800 A1 19990617
  31. Peptide-coated implants and methods for producing themBy Kessler, Horst; Finsinger, Dirk; Jonczyk, Alfred; Meyer, Joerg; Nies, Berthold; Kantlehner, Martin WO 9852619 A2 19981126

Publications

  1. Building block forum: A cost-effective business model to enhance access to diverse monomers and templatesBy Connell, Richard; Clark, Michael; Davie, Chris; Finsinger, Dirk; McLeod, Dale; Meerpoel, Lieven; Vasudevan, Anil; Willis, MikeAbstracts of Papers, 254th ACS National Meeting & Exposition, Washington, DC, USA, August 20-24, 2017 (2017), MPPG-15.
  2. Discovery of novel 7-azaindoles as PDK1 inhibitorsBy Wucherer-Plietker, Margarita; Merkul, Eugen; Mueller, Thomas J. J.; Esdar, Christina; Knoechel, Thorsten; Heinrich, Timo; Buchstaller, Hans-Peter; Greiner, Hartmut; Dorsch, Dieter; Finsinger, Dirk; et al Bioorganic & Medicinal Chemistry Letters (2016), 26(13), 3073-3080
  3. Fluctuating Open Teams(FLOT) - A New Approach to Boost Team Creativity and Innovation PotentialBy Ulrich A.K. Betz, Paul Czodrowski, Christina Esdar, Carl Deutsch, Norbert Beier, Dirk Finsinger, Bertram Cezanne, Klaus Urbahns, Margarita Wucherer-Plietker.Technology Transfer and Entrepreneurship; Volume 1 , Issue 2 , 2014
  4. Design and synthesis of isoquinolines and benzimidazoles as RAF kinase inhibitors By Buchstaller, Hans-Peter; Burgdorf, Lars; Finsinger, Dirk; Stieber, Frank; Sirrenberg, Christian; Amendt, Christiane; Grell, Matthias; Zenke, Frank; Krier, MireilleBioorganic & Medicinal Chemistry Letters (2011), 21(8), 2264-2269. 
  5. The discovery and optimization of hexahydro-2H-pyrano[3,2-c]quinolines (HHPQs) as potent and selective inhibitors of the mitotic kinesin-5 By Schiemann, Kai; Finsinger, Dirk; Zenke, Frank; Amendt, Christiane; Knoechel, Thorsten; Bruge, David; Buchstaller, Hans-Peter; Emde, Ulrich; Staehle, Wolfgang; Anzali, SoheilaBioorganic & Medicinal Chemistry Letters (2010), 20(5), 1491-1495.
  6. Cyclopropyl building blocks in organic synthesis. 124. Access to variously substituted 5,6,7,8-tetrahydro-3H-quinazolin-4-ones via Diels-Alder adducts of phenyl vinyl sulfone to cyclobutene-annelated pyrimidinonesBy Dalai, Suryakanta; Belov, Vladimir N.; Nizamov, Shamil; Rauch, Karsten; Finsinger, Dirk; de Meijere, ArminEuropean Journal of Organic Chemistry (2006), (12), 2753-2765. 
  7. Biofunctionalization of different surface types via αvβ3 integrin selective RGD peptidesBy Dahmen, Claudia; Hersel, Ulrich; Kantlehner, Martin; Auernheimer, Joerg; Finsinger, Dirk; Meyer, Joerg; Schaffner, Patricia; Jonczyk, Alfred; Diefenbach, Beate; Nies, Berthold; et alEdited By:Benedetti, Ettore; Pedone, CarloPeptides 2002, Proceedings of the European Peptide Symposium, 27th, Sorrento, Italy, Aug. 31-Sept. 6, 2002 (2002), 456-457. 
  8. Recent progress in the field of αv-integrin antagonistsBy Kessler, Horst; Kantlehner, Martin; Gibson, Christoph; Haubner, Roland; Finsinger, Dirk; Dechantsreiter, Michael; Planker, Eckart; Wermuth, Jochen; Schmitt, Jorg S.; Meyer, Jorg; et alFrom Peptides for the New Millennium, Proceedings of the American Peptide Symposium, 16th, Minneapolis, MN, United States, June 26-July 1, 1999 (2000), 235-237. 
  9. Surface coating with cyclic RGD peptides stimulates osteoblast adhesion and proliferation as well as bone formationBy Kantlehner, Martin; Schaffner, Patricia; Finsinger, Dirk; Meyer, Jorg; Jonczyk, Alfred; Diefenbach, Beate; Nies, Berthold; Holzemann, Gunter; Goodman, Simon L.; Kessler, HorstChemBioChem (2000), 1(2), 107-114.
  10. Intervesicle Cross-Linking with Integrin αIIbβ3 and Cyclic-RGD-Lipopeptide. A Model of Cell-Adhesion ProcessesHu, Bin; Finsinger, Dirk; Peter, Kai; Guttenberg, Zeno; Baermann, Michael; Kessler, Horst; Escherich, Achim; Moroder, Luis; Boehm, Jochen; Baumeister, Wolfgang; et alFrom Biochemistry (2000), 39(40), 12284-12294. 
  11. Selective RGD-mediated adhesion of osteoblasts at surfaces of implants By Kantlehner, Martin; Finsinger, Dirk; Meyer, Jorg; Schaffner, Patricia; Jonczyk, Alfred; Diefenbach, Beate; Nies, Berthold; Kessler, HorstFrom Angewandte Chemie, International Edition (1999), 38(4), 560-562.
  12. Regioselective thionylation of tertiary amide bonds in cyclic tetrapeptides - a conformational approach By Finsinger, Dirk; Konat, Robert K.; Schmitt, Wolfgang; Kessler, HorstEdited By:Ramage, Robert; Epton, RogerPeptides 1996, Proceedings of the European Peptide Symposium, 24th, Edinburgh, Sept. 8-13, 1996 (1998), 381-382. 
  13. Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the αvβ3 integrin for a new cancer therapyBy Haubner, Roland; Finsinger, Dirk; Kessler, HorstAngewandte Chemie, International Edition in English (1997), 36(13/14), 1374-1389. 
  14. Two novel probes reveal tubular and vascular Arg-Gly-Asp (RGD) binding sites in the ischemic rat kidneyBy Romanov, Victor; Noiri, Eisei; Czerwinski, Grzegorz; Finsinger, Dirk; Kessler, Horst; Goligorsky, Michael S.Kidney International (1997), 52(1), 93-102. 
  15. Cyclic peptides as pharmaceuticals By Finsinger, Dirk; Kessler, HorstFrom Praxis der Naturwissenschaften, Chemie (1996), 45(3), 2-6. 
  16. Design and superactive and selective integrin receptor antagonists containing the RGD sequenceBy Kessler, Horst; Diefenbach, Beate; Finsinger, Dirk; Geyer, Armin; Gurrath, Marion; Goodman, Simon L.; Hoelzemann, Guenter; Haubner, Roland; Jonczyk, Alfred; et al.Letters in Peptide Science (1995), 2(3/4), 155-60. 

Redirect

You have accessed https://www.emdgroup.com, but for users from your part of the world, we originally designed the following web presence https://www.merckgroup.com.

Let's go

Share Disclaimer

By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement